Efficacy and Safety of Lorundrostat for Uncontrolled and Treatment-resistant Hypertension: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Authors

Zain Ul Abideen, Muhammad Hassan Waseem, Areeba Shoaib, Tehreem Fatima, Muhammad Mukhlis, Nohela Rehman, Pawan Kumar Thada, Ameer Haider Cheema

Published in

Journal of cardiovascular pharmacology. Jul 01, 2026. Epub Jul 01, 2026.

Abstract

Uncontrolled hypertension remains a major contributor to cardiovascular morbidity and mortality. Lorundrostat directly reduces aldosterone synthesis and represents a targeted therapeutic strategy. This study aimed to evaluate the comparative efficacy and safety of lorundrostat among adults with uncontrolled or treatment-resistant hypertension. We conducted a systematic review and meta-analysis in accordance with the PRISMA 2020 guidelines and identified relevant RCTs from PubMed, ScienceDirect, and CENTRAL databases through August 2025. Data for various outcomes were extracted after computing the risk ratios (RRs) with 95% confidence intervals (CIs) for dichotomous outcomes and mean differences (MDs) with 95% CIs for continuous outcomes. We included 3 randomized controlled trials, with 1,165 patients receiving lorundrostat and 403 patients receiving placebo. The efficacy outcomes demonstrated a significant reduction in systolic blood pressure (SBP) (MD -8.00; 95% CI; -10.81 - -5.19; P<0.00001) and diastolic blood pressure (DBP) (MD -3.31; 95% CI; -5.56 - -1.07; P=0.004) with lorundrostat. Regarding safety outcomes, lorundrostat reported a higher incidence of adverse events (RR 1.47; 95% CI; 1.29 - 1.67; P<0.00001), hyperkalemia (RR 9.17; 95% CI; 2.24 - 37.44; P = 0.002), and symptomatic hypotension (RR 2.97; 95% CI; 1.12 - 7.90; P = 0.03), whereas the incidence of serious adverse events (RR 1.29; 95% CI; 0.33 - 5.03; P = 0.71) was comparable between the two groups. Lorundrostat effectively reduced blood pressure; however, its use was accompanied by increased adverse events, hyperkalemia, and symptomatic hypotension. Efficacy must therefore be weighed carefully against safety, taking into account the patients' baseline characteristics.

PMID:
42407048
Bibliographic data and abstract were imported from PubMed on 07 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.